Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01019187
RATIONALE: Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life of cancer survivors. Armodafinil may help relieve insomnia and fatigue in patients with cancer after chemotherapy. PURPOSE: This randomized phase II trial is studying how well cognitive behavioral therapy with or without armodafinil works in treating cancer survivors with insomnia and fatigue after chemotherapy.
Looking for future studies?
Notify Me21 year–75 year
All sexes
Interventional
Phase 2
Philadelphia, Pennsylvania, 19104, United States
Detailed DescriptionOBJECTIVES:
I. To determine if one or more of the intervention strategies (i.e., CBT-I, armodafinil, or both), when compared to a placebo only group, reduce insomnia in cancer patients following the conclusion of chemotherapy and/or radiation therapy.
II. To determine if one or more of the intervention strategies (i.e, CBT-I, armodafinil, or both), when compared to a placebo only group, reduce fatigue in cancer patients following the conclusion of chemotherapy and/or radiation therapy.
III. To determine if one or more of the intervention strategies (i.e., CBT-I, armodafinil, or both), when compared to a placebo only group, improve QOL in cancer patients following the conclusion of chemotherapy and/or radiation therapy.
OUTLINE: Patients are randomized to 1 of 4 treatment arms (cognitive behavioral therapy, armodafinil, both, or neither).
After completion of study treatment, patients are followed for 30 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ancillary Studies
Ancillary Studies
Given orally
Other names: PLCB
Other names: Fatigue Assessment/Management
Other names: Sleep disorders therapy
Given orally
Other names: Nuvigil
Other names: Complications of therapy management
Ancillary Studies
Other names: Compllications of therapy management
Other names: Fatigue Assessment/management
Time frame: Mid-point and end of treatment
Abramson Cancer Center at Penn Medicine
Other
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02088775
Adenocarcinoma, Adult Primary Hepatocellular Carcinoma
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT01705548
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial DetailsNCT00343460
Nausea, Nausea and Vomiting
Anniston, Alabama, United States
View Trial DetailsNCT00712712
Metastatic Cancer, Neoplasm Metastasis
Bordeaux, France
View Trial Details